Xiaobo Wang

Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET

M. Zhou, Xianzhong Zhang, Jianyang Fang, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

A novel 18F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice

Zhide Guo, Xianzhong Zhang, Jingchao Li, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

Xianzhong Zhang, Jianyang Fang, Shuo Hu, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Design, synthesis, and evaluation of novel tetrazoles featuring isoxazole moiety as highly selective antifungal agents.

Hao Wu, Liping Li, Da-Zhi Zhang, 2023, European journal of medicinal chemistry.

Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.

Jing Wang, Xianzhong Zhang, Yesen Li, 2021, Molecular pharmaceutics.

CD146‐mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR‐TKI resistance in lung cancer

Xiaoju Zhang, Nan Wei, Xiaobo Wang, 2019, The clinical respiratory journal.

Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET

M. Zhou, Xianzhong Zhang, Jianyang Fang, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging.

Zhide Guo, Yesen Li, Rongqiang Zhuang, 2024, ACS pharmacology & translational science.